CRISPRi/a screens in human iPSC-cardiomyocytes identify glycolytic activation as a druggable target for doxorubicin-induced cardiotoxicity
Cell Stem Cell · 2024
DOI: 10.1016/j.stem.2024.10.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Stem Cell, 2024. Verfasst von Chun Liu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA; Department of Physiology and Cancer Center, Milwaukee, WI, USA; Department…. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Doxorubicin, Myocytes, Cardiac, Cardiotoxicity. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, American Heart Association-American Stroke Association.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA; Department of Physiology and Cancer Center, Milwaukee, WI, USA; Department of Medicine and Cardiovascular Center, Medical College of Wisconsin,…
- Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA; Institute for Stem Cell Biology and Regenerative Medicine, Stanford, CA, USA; Department of Medicine (Division of Cardiology), Stanford, CA, USA.
- Department of Bioengineering, Stanford, CA, USA; Sarafan ChEM-H, Stanford University, Stanford, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA.
- Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA; Greentstone Biosciences, Palo Alto, CA, USA.
- Department of Biomedical Engineering, University of North Texas, Denton, TX, USA.
- Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA; Department of Medicine (Division of Cardiology), Stanford, CA, USA; Department of Surgery, Division of Vascular Surgery, Stanford University, St…
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- American Heart Association-American Stroke Association
- National Science Foundation
- CIRM
- California Institute of Regenerative Medicine
- American Heart Association
- Cancer Center, Medical College of Wisconsin
Zitieren
APA
Liu, C., Shen, M., Liu, Y., Manhas, A., Zhao, S. R., Zhang, M., Belbachir, N., Ren, L., Zhang, J. Z., Caudal, A., Nishiga, M., Thomas, D., Zhang, A., Yang, H., Zhou, Y., Ameen, M., Sayed, N., Rhee, J. W., Qi, L. S., & Wu, J. C. (2024). CRISPRi/a screens in human iPSC-cardiomyocytes identify glycolytic activation as a druggable target for doxorubicin-induced cardiotoxicity. Cell Stem Cell. https://doi.org/10.1016/j.stem.2024.10.007
Vancouver
Liu C, Shen M, Liu Y, Manhas A, Zhao SR, Zhang M, et al. CRISPRi/a screens in human iPSC-cardiomyocytes identify glycolytic activation as a druggable target for doxorubicin-induced cardiotoxicity. Cell Stem Cell. 2024. doi:10.1016/j.stem.2024.10.007
BibTeX
@article{Liu2024,
author = {Liu, Chun and Shen, Mengcheng and Liu, Yanxia and Manhas, Amit and Zhao, Shane Rui and Zhang, Mao and Belbachir, Nadjet and Ren, Lu and Zhang, Joe Z and Caudal, Arianne and Nishiga, Masataka and Thomas, Dilip and Zhang, Angela and Yang, Huaxiao and Zhou, Yang and Ameen, Mohamed and Sayed, Nazish and Rhee, June-Wha and Qi, Lei S and Wu, Joseph C},
title = {CRISPRi/a screens in human iPSC-cardiomyocytes identify glycolytic activation as a druggable target for doxorubicin-induced cardiotoxicity},
journal = {Cell Stem Cell},
year = {2024},
doi = {10.1016/j.stem.2024.10.007}
}
EUVIMED